KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Hologic (HOLX) EBITDA (2016 - 2025)

Hologic (HOLX) has disclosed EBITDA for 17 consecutive years, with $263.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 4.03% to $263.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $747.8 million through Dec 2025, down 20.23% year-over-year, with the annual reading at $823.2 million for FY2025, 16.16% down from the prior year.
  • EBITDA hit $263.3 million in Q4 2025 for Hologic, up from $236.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $796.8 million in Q1 2021 to a low of -$7.0 million in Q1 2025.
  • Historically, EBITDA has averaged $289.3 million across 5 years, with a median of $253.8 million in 2024.
  • Biggest five-year swings in EBITDA: soared 17328.57% in 2024 and later plummeted 103.33% in 2025.
  • Year by year, EBITDA stood at $641.3 million in 2021, then crashed by 59.08% to $262.4 million in 2022, then dropped by 24.47% to $198.2 million in 2023, then increased by 27.7% to $253.1 million in 2024, then grew by 4.03% to $263.3 million in 2025.
  • Business Quant data shows EBITDA for HOLX at $263.3 million in Q4 2025, $236.9 million in Q3 2025, and $254.6 million in Q2 2025.